Some data about a drug called APR-246 has come to light at the ongoing annual meeting of the American Society of Hematology in Orlando (which is not exactly a prime source for information about prostate cancer).
Filed under: Drugs in development | Tagged: APR-246, castration-resistant, mCRPC, metastatic, p53 | Leave a Comment »
Search for new and
ongoing trials on the
CTAG PCa web site
